Drilling for Bargains

Why It Matters

The valuation disconnect offers investors a high‑conviction, low‑cost entry into a sector poised for price appreciation as LNG demand and domestic gas prices rise.

Key Takeaways

• U.S. LNG exports projected to double by 2050, tightening domestic supply
• Henry Hub spot price expected $3.5/MMBtu in 2026, above $4 in winter
• NOPAT margin rose from 12% to 41% since 2024, boosting ROIC
• Generated $992M free cash flow, covering $808M share repurchases since 2023
• Stock priced for 60% profit decline, offering strong risk/reward upside

Pulse Analysis

U.S. liquefied natural gas (LNG) exports are on a steep growth trajectory, with the Energy Information Administration forecasting a rise from 15 billion cubic feet per day in 2025 to over 30 billion by 2050. This surge will siphon gas from domestic storage, tightening supply and supporting higher Henry Hub prices. Analysts expect spot prices to average $3.50 per MMBtu in 2026 and stay above $4 during winter, while longer‑term forecasts see $5‑$6 per MMBtu in the early 2030s.

Against this backdrop, the featured natural‑gas producer has leveraged its low‑cost inventory and efficient operations to deliver peer‑leading profitability. Since 2022, revenue and NOPAT have grown at a 7% compound rate, while NOPAT margins climbed from 12% to 41% after the 2024 price bottom. Return on invested capital surged to 28%, reflecting stronger capital efficiency. The company’s free cash flow of $992 million since 2023 not only exceeds its $808 million share‑repurchase program but also represents roughly a quarter of enterprise value, underscoring a solid balance‑sheet foundation.

Despite these fundamentals, the market has punished the stock, pricing it as if earnings will fall 60% permanently. This mispricing creates a compelling risk‑reward profile for investors seeking exposure to the natural‑gas upside without overpaying. Continued LNG export growth, sustained price premiums, and disciplined capital returns could close the valuation gap, delivering outsized returns for patient shareholders.